Trinity Biotech shares rise 10.34% after-hours after securing final regulatory approval for offshore Uni-Gold HIV test manufacturing.

Trinity Biotech surged 10.34% in after-hours trading following regulatory approval to commence upstream manufacturing of its Uni-Gold™ HIV rapid test under an offshored and outsourced production model. The clearance, the final regulatory milestone for this transition, is expected to expand gross margins, improve working capital efficiency, and enhance scalability for the WHO-prequalified test. This development aligns with the company’s Comprehensive Transformation Plan, signaling progress toward cost optimization and long-term financial stability. Concurrently, Trinity Biotech’s Premier Hb9210 HbA1c Analyzer achieved the top-tier IFCC Gold Classification for 2026, reinforcing its leadership in diabetes diagnostics. These milestones, coupled with a $9 million TrinScreen HIV order and strategic financial agreements, collectively drove investor optimism, outweighing prior concerns about debt and operational challenges.